Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Anil Jain, MD, FACP on The Prerequisite Infrastructure for Autonomous Healthcare — Innovaccer | VIVE 2026
Dr. Anil Jain, Chief Innovation Officer at Innovaccer, outlined the foundational infrastructure needed for autonomous healthcare during a VIVE 2026 interview. He highlighted the Gravity platform as an AI‑orchestration engine that links analytics to automated operational workflows, targeting high‑cost bottlenecks like prior authorization. Innovaccer is also expanding clinical depth through the Story Health integration for heart‑failure management, aiming to improve outcomes while protecting thin hospital margins. The strategic outlook points to industry‑wide consolidation around unified, intelligent platforms that can demonstrate clear ROI.
Healthcare Splits: MedTech Down, Biotech Outperforms Amid Rising Rates
Despite SPX back at new highs, Healthcare has proven dismal this year, & the bifurcation in this sector w/ Med Tech turning down while Biotech outperforms is not dissimilar w/ what happened in Technology early in the year. Given my expectations...
Bob Farrell on Applying E-Commerce Engagement to Healthcare — mPulse | VIVE 2026
Bob Farrell, executive at mPulse, explained how the company adapts e‑commerce engagement tactics to health‑care. By deploying conversational AI and omnichannel channels—SMS, email, rich‑media—mPulse delivers personalized outreach that nudges patients toward preventive screenings and medication adherence. Bain’s 2026 study cites...
Eli Ben-Joseph on The AI Co-Pilot that Reads the Entire Medical Record — Regard | VIVE 2026
Regard’s AI co‑pilot, led by co‑founder Eli Ben‑Joseph, claims to ingest and synthesize 100% of a patient’s electronic health record in real time, addressing the industry‑wide problem that physicians only review roughly 3‑5% of available data during a typical visit....
The Rise of the Generalist-Specialist
AI models are now passing specialist board exams, prompting a re‑imagining of clinical roles. Researchers propose "generalist‑specialists"—physicians who blend traditionally separate specialties such as cardiology, endocrinology and nephrology to manage disease domains holistically. This model promises fewer handoffs, faster diagnoses...
Don't Trust Unqualified Influencers; Demand Real Expertise
The PTs are lying to you. The surgeons are lying to you. The certifications are lying to you. But the guy with 40k followers doing band exercises in his garage? The influencer who made a $29 pain program over a weekend?...
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor‑Dex in Myeloma‑Induced Kidney
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/KJfqVVcwEr
Webster Equity Partners Secures $1.8 Billion for Largest Healthcare‑Services Fund
Webster Equity Partners announced the close of a $1.8 billion fund, the largest capital raise in its 23‑year history. The new vehicle will target buyout opportunities across the U.S. healthcare‑services sector, underscoring strong limited‑partner demand for specialized health‑care investments.
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/SKPUQiSaU4
Phase 3 Trial Tests Daratum
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/Hq9VlRCTCI
:max_bytes(150000):strip_icc():format(jpeg)/diagnosis-569695095f9b58eba49dd551.jpg)
Provisional Diagnosis Vs. Differential Diagnosis
A provisional diagnosis is a clinician’s initial, best‑guess label applied when information is incomplete, allowing treatment to begin while further data are collected. In contrast, a differential diagnosis is a systematic list of all plausible conditions that must be evaluated...
Covista Teams with Google Cloud to Launch AI‑Powered Classroom for Healthcare Education
Covista, the nation’s largest healthcare educator, announced a partnership with Google Cloud to develop an AI‑powered classroom embedded in Canvas. The platform, slated for a pilot later this year, aims to deliver precision, personalized learning for medical students across Covista’s...
FDA Looks East—Here’s What Industry Needs to Know
The FDA’s FY2027 budget proposes $2.5 million and five new full‑time staff to open foreign offices in Hanoi, Vietnam, and Tokyo, Japan, expanding its inspection footprint in East Asia. The request follows FY2026 congressional language urging permanent presence for unannounced inspections...
Four Candidates Target Ultra‑Rare Polish PUS3 Syndrome
“We have four drug candidates for patients with an ultra-rare disease with Polish origins, the PUS3 syndrome; one of these candidates will be used in practice,” Lisowski said. https://t.co/GTJbPQSdXQ
NHS Doctors' Strike Reveals Faster Care but Raises Sustainability Concerns
A five‑day strike by 25,000 British doctors in December led to faster patient flow and lower bed occupancy, with A&E targets hit 82% of the time. Hospital leaders praise the efficiency boost, yet clinicians warn the model cannot replace long‑term...
When to Stop Myeloma Treatment: MRD Insights
MT @hhashmi87 #IMS25 Great Meet The Expert talk by @bdermanmd on MRD in Myeloma Risk vs benefit Who can stop treatment Active surveillance post discontinuation #mmMRD #mmsm https://t.co/FIDPrE7QRb
MRD‑negative Patients May Stop Myeloma Maintenance Therapy
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 https://t.co/FBTY7SnCxK #NCT04108624 #mmsm #mmMRD
What Your Wearable Knows That Your Doctor Ignores: Weekly Livestream W/ Brooks Leitner
The Food is Health newsletter is hosting a live stream on April 17 at 2 p.m. ET with Dr. Brooks Leitner, a Yale‑trained physician‑scientist and co‑founder of VO Health. The discussion will focus on VO2 max, a fitness metric that research shows...
ODAC Approves MRD as Early Endpoint for Myeloma Trials
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrpVeR #mmMRD #mmsm #ctsm @FDAOncology https://t.co/V4wrNgvTrG
Clinicians Show Mixed Adoption of Myeloma MRD Testing
Clinician attitudes and practices toward measurable residual disease in multiple myeloma [Jun 7, 2020] @bdermanmd @jagoda_jasielec @ajjakubowiak Brit J Haematol https://t.co/8zhxYfYwZQ #mmsm #mmMRD https://t.co/mPtRCjnB9f
Australia’s Aged Care Algorithm Is Under Fire. At Last, Someone’s Listening
Australia’s Support at Home program uses a digital Integrated Assessment Tool that feeds an algorithm to set home‑care funding levels. Critics argue the algorithm lacks public validation, combines eleven error‑prone assessments, and cannot be manually overridden, raising concerns about under‑funded...
Vaccines Vanishing Threatens Global Health Catastrophe
The Horrors That Could Lie Ahead if Vaccines Vanish — @propublica good article on the work of @NathanLo3579 @Stanford my former mentee and amazing colleague https://t.co/n9oUgkvOZ7
Accreditation 360: Why Compliance Fails Without Strategy (Data) | ClearPoint Strategy Blog
ClearPoint Strategy analyzed over 30,000 strategic plans and found that hospitals treating Joint Commission Accreditation 360 as a compliance checklist stumble, while those embedding it in strategic management thrive. The data shows hospitals track an average of 1,241 compliance measures, yet...
AI‑Enhanced Depression Screening Merges LLMs with Psychometric Tools for Faster, Nuanced Diagnosis
Researchers publishing in JMIR Formative Research unveiled an AI‑driven depression screening method that pairs large language models with standard psychometric scales, delivering real‑time, nuanced assessments. The hybrid approach promises higher detection accuracy while preserving the speed of traditional tools.
Researchers Unveil Mastery-Based CBT Model to End Kids' Chronic Nightmares
A team of sleep scientists has introduced DARC‑NESS, a mastery‑based cognitive‑behavioral model designed to treat chronic nightmares in children. Published in Frontiers in Sleep, the framework emphasizes confidence‑building and coping skills to restore healthy sleep patterns and reduce downstream mental‑health...
UT Southwestern Study Finds Brain Cells Crucial to Endurance Performance
UT Southwestern Medical Center announced that new research identifies distinct brain cells that regulate endurance, showing stamina is not solely muscle‑based. The finding could pave the way for therapies that mimic exercise benefits for people unable to work out.
Ketone Ester Cut Alcohol Cravings in Small Study, Offering New Biohack
Researchers led by Xinyi Li reported that a single 395 mg/kg dose of a ketone ester supplement sharply reduced alcohol cravings in participants with alcohol use disorder and redirected brain metabolism from glucose to ketones. The pilot study, published in Psychiatry...
Indiana Leads State Push for Three‑Month Medicaid Work Rule, Affecting 33% of Enrollees
Indiana Gov. Mike Braun signed a law on March 4 mandating a three‑month work‑history for Medicaid applicants, covering about a third of the state’s recipients. The move follows new federal guidelines that require at least one month of work, with states...
J&J Lifts 2026 Sales Outlook to $100 B, Defying Pricing Headwinds
Johnson & Johnson announced a 2026 sales guidance of $99.5‑$100.5 billion, topping the Street’s $98.9 billion consensus. The raise comes after a $3.05 billion acquisition and a pricing‑cost deal, underscoring strong oncology momentum and operational resilience.
FDA Issues Draft Guidance to Standardize Safety Assessment of Genome‑Editing Gene Therapies
The U.S. Food and Drug Administration today released a draft guidance titled “Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next‑Generation Sequencing.” The document sets uniform pre‑clinical and IND requirements for ex vivo and in vivo CRISPR‑based...
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)
Chinese biopharma Mabwell announced that the National Medical Products Administration has accepted a supplemental biologics license application for MAIWEIJIAN, its denosumab biosimilar. The 120 mg injection, already approved in China for giant cell tumor of bone and in Pakistan, is now...
Axtria Acquires Conexus Solutions to Fuse AI and CRM in Life Sciences
Axtria announced the acquisition of Conexus Solutions, a leading CRM transformation partner, to combine its agentic AI platform with Conexus' Veeva and Salesforce capabilities. The deal, disclosed on April 15, 2026, positions Axtria to deliver an integrated intelligence layer for...
Cera Invests Eight‑figure Sum to Launch World‑first AI Care Lab in London
Cera announced an eight‑figure (≈ $7 million) investment to open a government‑backed AI care lab in London, aiming to develop tools that cut NHS workload and reduce avoidable hospital stays. The initiative brings together AI experts and entrepreneurs in residence, leveraging Cera’s...
Glioblastoma's Immune Microenvironment Blocks Checkpoint Therapy
The glioblastoma tumor immune microenvironment (TIME) is an immunosuppressive barrier to therapy that encumbers glioblastoma responses to immune checkpoint inhibition (ICI). https://t.co/rgIKZ8N0Q4
Tenet Healthcare CIO Paola Arbour to Retire Dec. 31, Stays Part‑Time Through 2028
Tenet Healthcare announced that CIO Paola Arbour will retire on Dec. 31, 2026, but will continue part‑time through April 1, 2028, earning $820 per week for transition services. The move comes as the for‑profit hospital chain, which runs 50 hospitals in eight...
Dear MAUDE: Is iRestore Just a Hair-Growth Helmet?
The iRestore Elite hair‑growth helmet, marketed as a Class II FDA‑cleared infrared lamp, has sold over 500,000 units and is used daily for twelve minutes. Investigations reveal the device stems from Freedom Laser Therapy, a company that originally offered laser‑based quit‑smoking...
Newfund Closes €60 Million Neuro‑Tech Fund, Europe’s First Dedicated Brain‑Tech VC
Newfund announced the closing of a €60 million ($65 million) venture fund dedicated to neuro‑technology companies, reaching its hard‑cap within weeks. The fund, the first of its kind in Europe, aims to back early‑stage startups developing brain‑computer interfaces, neuro‑diagnostics and cognitive‑enhancement tools,...
Travere's FILSPARI Gains Full FDA Approval as First FSGS Therapy
Travere Therapeutics announced that the FDA has granted full approval to FILSPARI® (sparsentan) for adult and pediatric patients with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. The decision makes FILSPARI the first and only FDA‑approved therapy for this rare kidney...
Effect of ‘Gamechanger’ Alzheimer’s Drugs ‘Trivial’, Review Concludes
A new Cochrane Review of 17 clinical trials involving more than 20,000 participants found that anti‑amyloid drugs—including lecanemab and donanemab—produce only trivial cognitive benefits and modest functional gains over 18 months. The analysis also highlighted a higher incidence of brain...
Improving Immunotherapy in Solid Tumors Using FMT
Recent phase 2 trials demonstrate that fecal microbiota transplantation (FMT) significantly improves the efficacy of first‑line immune checkpoint inhibitors in renal cell carcinoma, cutaneous melanoma, and non‑small cell lung cancer. The benefit is linked to functional remodeling of the gut...
Enhancing Antitumour Nanovaccine Efficacy via Integrated Cholesterol Modulation in Situ
Researchers have created a nanovaccine, NPCM‑OT, that simultaneously delivers tumor antigens and depletes cholesterol from dendritic cell membranes. The cholesterol reduction reshapes lipid microdomains, enhancing immune‑synapse formation and CD8⁺ T‑cell activation. In multiple mouse tumor models, the vaccine showed both...
Exploring the Lung-Brain Axis in Perioperative Neurocognitive Disorders: A Potential Therapeutic Target
Recent research highlights the lung‑brain axis as a promising therapeutic target for perioperative neurocognitive disorders (PNDs). Studies reveal that general anesthesia reshapes the lung microbiome, while lung‑derived immune cells and cytokine pathways can modulate amyloid‑beta and tau pathology in the...
The Hallmarks of Cancer: 25 Years Guiding Discovery and Therapy
Twenty‑five years after the original six Hallmarks of Cancer were proposed, Douglas Hanahan updates the framework to incorporate new hallmarks such as deregulated metabolism, immune evasion, and the tumor microenvironment. Advances in genomics, single‑cell and spatial profiling have deepened insight...
Targeting Genomic Instability in Cancer
Genomic instability fuels cancer evolution and simultaneously creates therapeutic vulnerabilities. Decades of genotoxic chemotherapy and radiation have given way to precision approaches that exploit DNA‑damage response (DDR) defects, most notably PARP inhibitors for BRCA‑mutated tumors. The pipeline now includes dozens...
Quantum Computers Take on Health Care: Light-Sensitive Cancer Drugs Win US$2-Million Contest
A team comprising Algorithmiq, IBM, and the Cleveland Clinic secured the $2 million Quantum for Bio prize by demonstrating a hybrid quantum‑classical simulation of a light‑sensitive cancer drug. The approach models photon‑electron interactions on IBM’s Quantum System One, revealing how molecular...
The FDA Just Rewrote the Rules for Gene Therapy Approval & Most Investors Haven’t Noticed Yet: The Plausible Mechanism Framework...
The FDA released two draft guidances in early 2026 that reshape gene‑therapy regulation. The Plausible Mechanism Framework (PMF) creates a formal pathway for individualized, ultra‑rare treatments, allowing single‑patient or tiny‑cohort data combined with mechanistic and natural‑history evidence to support marketing...
UC Patient Care and Service Workers Plan Open-Ended Strike Starting Next Month
Tens of thousands of University of California patient‑care and service workers will begin an open‑ended strike on May 14 after contract talks stalled. The AFSCME Local 3299 union, representing roughly 42,000 custodial, cafeteria, X‑ray, respiratory and other staff, says wages,...
Estrogen Is Estrogen As Far As Your Uterus Is Concerned
The article challenges the common claim that transdermal, “bioidentical” estradiol is safer for the uterus than other estrogen therapies. It explains that any estrogen that activates the ERα receptor drives endometrial cell division, regardless of its source. By comparing transdermal...
Gut Microbiome Fuels Worse Infections in Fatty Liver
Alterations in the gut microbiome significantly worsen bacterial infection outcomes in fatty liver disease by increasing liver damage and inflammation, highlighting the gut–liver axis as a potential target for new therapies. guthealth
Rethinking Healthcare: Julie Yoo on Infinite Growth
I really enjoyed interviewing @a16z 's @julieyoo : Rethinking the Rules: Julie Yoo on Infinite Healthcare, Compound Businesses, and the New Investor Playbook https://t.co/fdIq6NbQ7b cc @startuphealth